GT BIOPHARMA, INC. Cash
GT BIOPHARMA, INC. (GTBP) had Cash of $10.00 million as of 2023-12-31, per its 10-K filed 2024-03-26.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:Cash · last filed 2024-03-26
- 2023-12-31: Cash $10.00M.
- 2021-09-30: Cash $9.68M.
- 2021-06-30: Cash $39.51M.
- 2021-03-31: Cash $27.55M.
| Period end | Cash |
|---|---|
| 2023-12-31 | $10.00M 10-K · filed 2024-03-26 |
| 2021-09-30 | $9.68M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $39.51M 10-Q/A · filed 2021-12-29 |
| 2021-03-31 | $27.55M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $5.30M 10-Q/A · filed 2021-12-29 |
| 2020-09-30 | $350.00K 10-Q · filed 2021-11-10 |
| 2020-06-30 | $851.00K 10-Q/A · filed 2021-12-29 |
| 2020-03-31 | $5.00K 10-Q · filed 2021-05-17 |
| 2019-12-31 | $28.00K 10-Q/A · filed 2021-12-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |